SCHEMBL15907209

SCHEMBL15907209

C#Cc1cc(NC(=O)c2ccc(C(N)=O)cc2)ccc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.50
RAB9A P51151 8/20 0.50
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KIT P10721 1/20 0.47
MAPT P10636 4/20 0.47
BCAT2 O15382 1/20 0.47
F2 P00734 1/20 0.45
PLG P00747 1/20 0.45
PLAU P00749 1/20 0.45
KLKB1 P03952 1/20 0.45
PRSS1 P07477 1/20 0.45
FKBP5 Q13451 1/20 0.45
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 2/20 0.44
CSF1R P07333 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907178 0.92 BCAT2 (0.54) NPC1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL19500722 0.86 NPC1 (0.52) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL17935977 0.84 NPC1 (0.61) NPC1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL17935980 0.84 TRPV1 (0.56) NPC1RAB9AKMT2AMEN1KIT
SCHEMBL13022989 0.84 KIT (0.48) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL18323173 0.83 NPC1 (0.49) NPC1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL13400513 0.83 KMT2A (0.51) NPC1RAB9AKMT2ASMN1; SMN2KDM4E
SCHEMBL17936108 0.81 KIT (0.50) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL19500727 0.81 MEN1 (0.64) NPC1RAB9AKMT2AKDM4EMEN1
SCHEMBL19500733 0.81 HSD11B1 (0.46) NPC1RAB9AKMT2AKITFKBP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 NPC1 3370/4885RAB9A 1864/4885KMT2A 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.